Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier

Kumar Tekwani Movellan1, Melanie Wegstroth1, Kerstin Overkamp1

  • 1Department of NMR Based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, Göttingen, Germany.

Insights

Rimantadine binding to the influenza A M2 protein pore is hindered by slow kinetics and protein structural changes. Cholesterol and pH significantly impact drug binding within viral lipid environments.

Area of Science:

  • Biophysics
  • Structural Biology
  • Virology

Background:

  • Rimantadine targets the M2 protein pore of influenza A, crucial for viral efficacy.
  • Incomplete drug binding was observed in specific lipid environments, posing a challenge to understanding its mechanism.

Purpose of the Study:

  • Investigate the reasons behind incomplete Rimantadine pore binding in lipid bilayers.
  • Characterize the kinetics and environmental factors influencing drug-M2 protein interactions.

Main Methods:

  • Utilized 55-100 kHz magic-angle spinning NMR to study drug binding kinetics.
  • Analyzed binding in three distinct lipid environments: DPhPC, DPhPC with cholesterol, and viral mimetic bilayers.
  • Determined resonance assignments and tracked chemical shift changes in real-time.

Main Results:

  • Identified slow binding kinetics and protein structural changes as key factors limiting pore binding.
  • Demonstrated that cholesterol and pH significantly affect Rimantadine binding kinetics.
  • Observed that pore binding disrupts the histidine 37 imidazole-imidazole hydrogen bond, impacting M2 protein solubilization.

Conclusions:

  • Slow binding kinetics and lipid environment, particularly cholesterol, influence Rimantadine efficacy.
  • Understanding these interactions is vital for developing effective influenza A antivirals.
  • The M2 protein's structural dynamics play a critical role in drug binding and viral function.

Related Concept Videos

Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
647
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.8K